Nailing the Diagnosis Without the Rabbit Hole
Neita and Miranti open with the question every CSU patient asks the moment they walk in: "What is this?" As their guest Dr. Alexandra Golant explains, these patients feel out of control, and by the time they reach the office the hives are usually gone — leaving the clinician to work off history and the patient's phone album of photos.
Golant keeps it grounded in the basics. By definition, a true wheal should not stay in the same spot for more than 24 hours; it should be evanescent. When a patient has a lesion during the visit, she'll ask whether it was there at the same time yesterday. She also wants duration, what the patient has already tried, and whether she's their first stop -details that help her label the disease and even predict trajectory.
The hosts and Golant clarify the categories. Inducible urticaria has a clear, reproducible trigger — pressure, cold plunges, vibration from a drill, exercise — whereas chronic spontaneous urticaria means, as Golant puts it, "we don't know why it's happening." The accepted cutoff for chronic disease remains six weeks, and Golant notes most patients have already crossed that threshold by the time they reach dermatology, though not always.
Skip the Endless Testing
One of the episode’s strongest themes is Golant's push against exhaustive workups. A biopsy, she says, in the best case only confirms a wheal and often misses the acute inflammation the pathologist needs anyway. Extensive testing simply isn't necessary-and that's backed by the guidelines, which recommend against obsessively excluding diagnoses far less common than CSU.
Golant draws a parallel to prurigo nodularis and other conditions where the patient-driven hunt for a root cause traps people in unproductive cycles-dermatologist to allergist to naturopath, sometimes spending thousands or tens of thousands of dollars on things like mold testing. Even a positive allergen or a mold finding, she warns, usually isn't the trigger of the CSU. Her stance: "Why don't we treat what we see today?" Testing can be pursued or referred without delaying relief.
When patients arrive armed with internet, Reddit, or Facebook-group narratives, Golant increasingly leans on the guidelines to reassure them — the same way she explains guideline-based care to an atopic dermatitis patient asking for intramuscular triamcinolone. She frames it not as withholding, but as practicing evidence-based medicine that won't spin their wheels.
Angioedema and When to Worry
Miranti admits angioedema still makes her nervous — is there airway compromise, is this anaphylaxis? Golant offers reassurance rooted in the data: in the context of confirmed CSU, the presence of angioedema is not a harbinger of laryngeal edema and shouldn't fundamentally change management.
The caveats matter. Isolated angioedema without hives, or anything atypical about the story, is a different situation. If alarm bells are going off that this might not be CSU, that's the moment to pause and refer out.
Treatment and Reclaiming the Space
For a treatment-naive patient, Golant still starts with a proper antihistamine regimen — above standard OTC dosing, mixing sedating and non-sedating agents, going up as needed. What matters is confirming the patient has truly done it and running trials at short intervals rather than dragging them out over months.
When symptoms return before the next antihistamine dose, when control isn't holding, or when the patient can't tolerate the dose they need, Golant moves early and openly to advanced therapies now approved for CSU — the newest being dupilumab, with omalizumab available before it.
Golant traces the drift of CSU out of dermatology to omalizumab's approval around 2014; its anaphylaxis risk and monitoring needs made many dermatologists uncomfortable, and the condition migrated toward allergy and immunology colleagues comfortable with testing and crash carts. With dupilumab now available — a therapy dermatologists already know well and keep in the fridge — she sees a chance to "take back CSU." The hosts close by challenging the audience to get comfortable diagnosing and managing this underserved disease and to own the space.